BioSim, Spanish Association of Biosimilar Medicines, is a non-profit organization whose aim is to welcome and represent all pharmaceutical companies established in Spain that research, develop, produce and/or market biosimilar medicines.
A strategic vision of biosimilar medicines: national – and European – approach to inspire other regions. Ilaphar
Biosimilars in figures. biosim
Biosimilars: the key to access to health. microBacterium
Communication and information guide for nurses. Management of changes between similar biological medications. European Specialist Nurses Organization
The impact of an evergreening strategy near patent expiration on biosimilar adoption and public healthcare costs: a case study on the introduction of a second form of administration of trastuzumab in the Netherlands. The European Journal of Health Economics
Conference for patients 'Biosimilars: quality, safety and efficiency'
Conference held by BioSim in collaboration with the Spanish Patient Forum (FEP), in order to train and inform patients about biosimilars.
A biosimilar (or similar biological medicine) is a biological medicine equivalent in quality, efficacy and safety to an original biological medicine, called a reference product. The dosage and route of administration must be the same, and the biosimilar is authorized for all or some of the indications approved for the reference biologic.
The main, but not the only, added value attributable to the entry of biosimilars is the possibility that a greater number of patients have access to biological treatments. In other words, due to the cost reduction compared to the original product, the main beneficiary of the incorporation of biosimilar medicines into healthcare systems are the patients.
Biological medicines have represented a notable advance in the treatment of diseases that are generally serious and chronic (but not only). In many cases, these are already therapeutically essential medicines, but whose average cost is much higher than that of chemically synthesized medicines.